238 results
8-K
EX-99.1
33w6tb
14 Nov 22
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:39pm
DEFA14A
a4ceb
30 Sep 22
Additional proxy soliciting materials
4:18pm
8-K
EX-2.1
1u302fub2pzmnbor
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
i8p4t8b2r v22d
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
DEFA14A
EX-99.2
jf2ahhe q2zls
28 Sep 22
Additional proxy soliciting materials
4:59pm
DEFA14A
EX-99.1
iz9h34nm
28 Sep 22
Additional proxy soliciting materials
4:59pm
8-K
EX-99.2
9vpwqhi2v2kgcmltp
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
EX-99.1
as1g6hnax5msy3888l
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
EX-99.1
kc2j2t9uq 1ie9i9jxx
17 May 22
Idera Pharmaceuticals Shares Positive Results from Investigator- Sponsored Trial in Melanoma Patients at Amsterdam UMC
10:14am